Literature DB >> 21683309

Successful treatment with adalimumab in a familial case of gastrointestinal Behcet's disease.

Chiara De Cassan1, Bénédicte De Vroey, Catherine Dussault, Eric Hachulla, Sebastien Buche, Jean-Frédéric Colombel.   

Abstract

We present here two siblings with a history of recurrent oral and genital ulcers, neurological and gastrointestinal manifestations. The diagnosis of Behçet's disease in a context of familial aggregation was assumed. Facing repeated steroid-dependent flares and failure of maintenance therapies with colchicine and intolerance to pentoxifilline and disulone, adalimumab was started. Rapid response was observed in both patients, with clinical remission after induction therapy, which currently sustains under maintenance schedule. This case report suggests the effectiveness of adalimumab as first anti-TNFα in case of steroid-dependent/resistant gastrointestinal BD.
Copyright © 2011 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21683309     DOI: 10.1016/j.crohns.2011.03.006

Source DB:  PubMed          Journal:  J Crohns Colitis        ISSN: 1873-9946            Impact factor:   9.071


  16 in total

Review 1.  Update on the therapy of Behçet disease.

Authors:  Zeinab Saleh; Thurayya Arayssi
Journal:  Ther Adv Chronic Dis       Date:  2014-05       Impact factor: 5.091

Review 2.  The development and assessment of biological treatments for children.

Authors:  Eve M D Smith; Helen E Foster; Michael W Beresford
Journal:  Br J Clin Pharmacol       Date:  2015-03       Impact factor: 4.335

Review 3.  Gastrointestinal Behçet's disease: a review.

Authors:  Wasseem Skef; Matthew J Hamilton; Thurayya Arayssi
Journal:  World J Gastroenterol       Date:  2015-04-07       Impact factor: 5.742

4.  Longitudinally extensive transverse myelitis as the sole presentation of neuro-Behçet's disease responding to infliximab.

Authors:  Ian Coulter; Saif Huda; Atik Baborie; Anu Jacob
Journal:  J Spinal Cord Med       Date:  2012-02-08       Impact factor: 1.985

5.  Mimicry and deception in inflammatory bowel disease and intestinal behçet disease.

Authors:  Erika L Grigg; Sunanda Kane; Seymour Katz
Journal:  Gastroenterol Hepatol (N Y)       Date:  2012-02

Review 6.  Update on the Treatment of Behcet's Disease of the Small Bowel with Biologic Agents.

Authors:  Yehyun Park; Jae Hee Cheon
Journal:  Curr Gastroenterol Rep       Date:  2020-03-19

7.  Development of Immunopathogenesis Strategies to Treat Behçet's Disease.

Authors:  Osman Köse
Journal:  Patholog Res Int       Date:  2012-04-03

Review 8.  Adalimumab in the management of Behçet's disease.

Authors:  Atsuhisa Ueda; Mitsuhiro Takeno; Yoshiaki Ishigatsubo
Journal:  Ther Clin Risk Manag       Date:  2015-04-13       Impact factor: 2.423

Review 9.  Anti-TNF-alpha therapy and systemic vasculitis.

Authors:  Pierre-André Jarrot; Gilles Kaplanski
Journal:  Mediators Inflamm       Date:  2014-02-27       Impact factor: 4.711

Review 10.  Off-label uses of anti-TNF therapy in three frequent disorders: Behçet's disease, sarcoidosis, and noninfectious uveitis.

Authors:  Daniel Sánchez-Cano; José Luis Callejas-Rubio; Ricardo Ruiz-Villaverde; Raquel Ríos-Fernández; Norberto Ortego-Centeno
Journal:  Mediators Inflamm       Date:  2013-08-01       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.